Effectiveness and safety of COVID-19 vaccination in people with blood cancer
Our study provides robust evidence which supports the use of COVID-19 vaccinations for people with blood cancer. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 5, 2024 Category: Cancer & Oncology Authors: Emma Copland, Jennifer Hirst, Emma Mi, Martina Patone, Daniel Chen, Carol Coupland, Julia Hippisley-Cox Tags: Original Research Source Type: research
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
The safety and efficacy of first-line durvalumab in PS2 patients with advanced NSCLC is unknown. Here, we present the primary analysis of first-line durvalumab in PS2 patients, unsuitable for combination chemotherapy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 5, 2024 Category: Cancer & Oncology Authors: Michael Mark, Patrizia Froesch, Katrin Gysel, Sacha I. Rothschild, Alfredo Addeo, Christoph J. Ackermann, Sabrina Chiquet, Martina Schneider, Karin Ribi, Angela Fischer Maranta, Sara Bastian, Roger von Moos, Markus Joerger, Martin Fr üh, for the Swiss Gr Tags: Original Research Source Type: research
Burden of comorbidities: Osteoporotic vertebral fracture during non-small cell lung cancer - the BONE study
This study aims to evaluate the prevalence and incidence of osteoporotic vertebral fracture (OPVF) during NSCLC follow-up, identify risk factors of OPVF, and determine the impact on overall survival (OS). (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 5, 2024 Category: Cancer & Oncology Authors: E. Ebstein, P. Brocard, G. Soussi, R. Khoury, M. Forien, A. Khalil, C. Vauchier, PA Juge, B. L éger, S. Ottaviani, P. Dieudé, G. Zalcman, V. Gounant Tags: Original Research Source Type: research
Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy
This study aims to evaluate the impact of adjuvant anti-PD1 therapy on the health-related quality of life (HRQOL) of patients with resected stage III/IV melanoma (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 3, 2024 Category: Cancer & Oncology Authors: Mees Egeler, Julia Lai-Kwon, Renaud Tissier, Itske Fraterman, Anke Kuijpers, Winan Van Houdt, Sofie Wilgenhof, Aparna Rao, Shahneen Sandhu, Rebecca Lee, Hanna Eriksson, Marieke van Leeuwen, Kelly de Ligt, Alexander van Akkooi, Lonneke van de Poll-Franse Tags: Original Research Source Type: research
Corrigendum to “Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer” [Eur J Cancer 180 (2023) 184–185]
The authors regret that an error was made in the detail for affiliation c. The correct affiliation is: Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 2, 2024 Category: Cancer & Oncology Authors: Fan Yang, Guanmo Liu, Feng Mao, Yong-Chang Zheng Tags: Corrigendum Source Type: research
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: analysis of the NIVOREN GETUG-AFU 26 study
Immune checkpoint inhibitors are standard of care in metastatic renal cell carcinoma but their activity and safety in elderly patients is insufficiently explored. We evaluated outcomes of elderly patients with mRCC treated with nivolumab in the GETUG-AFU 26 NIVOREN phase 2 trial (NCT03013335) and conducted exploratory circulating biomarker analyses. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 2, 2024 Category: Cancer & Oncology Authors: Lo ïc Mourey, Larissa Tames Rainho, Cécile Dalban, Lucía Carril-Ajuria, Sylvie Negrier, Christine Chevreau, Gwenaëlle Gravis, Constance Thibault, Brigitte Laguerre, Philippe Barthelemy, Delphine Borchiellini, Marine Gross-Goupil, Lionnel Geoffrois, Tags: Original Research Source Type: research
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)
TLD-1 is a novel liposomal doxorubicin that compared favorably to conventional doxorubicin liposomal formulations in preclinical models. This phase I first-in-human study aimed to define the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), safety and preliminary activity of TLD-1 in patients with advanced solid tumors. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 2, 2024 Category: Cancer & Oncology Authors: Ilaria Colombo, Kira-Lee Koster, Lisa Holer, Simon Haefliger, Manuela Rabaglio, Sara Bastian, Michael Schwitter, Katrin Eckhardt, Stefanie Hayoz, Anna M. Mc Laughlin, Charlotte Kloft, Marian Klose, Stefan Halbherr, Christian Baumgartner, Cristiana Sessa, Tags: Original Research Source Type: research
Editorial Board
(Source: European Journal of Cancer)
Source: European Journal of Cancer - February 1, 2024 Category: Cancer & Oncology Source Type: research
Obituary: Nobel Laureate Harald zur Hausen (1936 –2023) - Who dedicated his life to unraveling the role of infectious agents in the pathogenesis of human cancers
Harald zur Hausen was born in 1936 in Gelsenkirchen as the fourth child of Manfred and Melanie zur Hausen. At an early age, he developed a deep interest in birds and other living animals and decided to become a natural scientist later in life. In 1955, he finished school and began studying medicine and biology at the universities of Bonn, Hamburg, and finally D üsseldorf. In his biology classes, he learned about lysogenic bacteriophages and their ability to reprogram the genetic information of their host bacteria. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 31, 2024 Category: Cancer & Oncology Authors: Michael Baumann, Magnus von Knebel Doeberitz Source Type: research
Obituary: Nobel Laureate Harald zur Hausen (1936 - 2023) -who dedicated his life to unraveling the role of infectious agents in the pathogenesis of human cancers
© Uwe Anspach / DKFZ (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 31, 2024 Category: Cancer & Oncology Authors: Michael Baumann, Magnus von Knebel Doeberitz Source Type: research
Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival
In this study, we evaluated the clinical relevance of molecular features to identify patients at risk of chemoresistance, relapse and death of disease. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 31, 2024 Category: Cancer & Oncology Authors: Aurore Pire, Theo Z Hirsch, Guillaume Morcrette, Sandrine Imbeaud, Barkha Gupta, Jill Pilet, Marianna Cornet, Monique Fabre, Catherine Guettier, Sophie Branchereau, Laurence Brugi ères, Florent Guerin, Véronique Laithier, Carole Coze, Genta Nagae, Eiso Tags: Original Research Source Type: research
Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer
The role of molecular classification in patients with low/intermediate risk endometrial cancer (EC) is uncertain. Higher precision in diagnostics will inform the unsettled debate on optimal adjuvant treatment. We aimed to determine the association of molecular profiling with patterns of relapse and survival. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 31, 2024 Category: Cancer & Oncology Authors: Kristina Lindemann, Wanja Kildal, Andreas Kleppe, Kari Anne R Tobin, Manohar Pradhan, Maria X. Isaksen, Ljiljana Vlatkovic, H åvard E. Danielsen, Gunnar B. Kristensen, Hanne A. Askautrud Tags: Original Research Source Type: research
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
This study estimated associations of NSAIDs with recurrence-free survival (RFS), distant metastasis-free survival (DMFS) and the incidence of immune-related adverse events (irAEs) in high-risk patients with resected melanoma in the EORTC 1325/KEYNOTE-054 phase III clinical trial. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 29, 2024 Category: Cancer & Oncology Authors: Oliver John Kennedy, Nina Glassee, Michal Kicinski, Christian U. Blank, Georgina V. Long, Victoria G. Atkinson, St éphane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A Tags: Original Research Source Type: research
Recent Advances and Future Strategies in First-Line Treatment of ES-SCLC
Recent advancements in treating extensive-stage small-cell lung cancer (ES-SCLC) have been significantly marked by incorporating immune checkpoint inhibitors (ICIs) into platinum-based chemotherapy, leading to modest yet notable improvements in patient outcomes, which become more evident with longer follow-up. However, critical challenges persist, such as identifying effective biomarkers for accurate patient selection or finding more effective drugs. This review delves into the current and evolving treatment landscape for ES-SCLC, focusing on the most promising therapeutic strategies under investigation. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 28, 2024 Category: Cancer & Oncology Authors: Igor Gomez-Randulfe, Rita Leporati, Brinda Gupta, Stephen Liu, Raffaele Califano Tags: Review Source Type: research
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial
In the BROCADE3 study, the addition of veliparib to carboplatin plus paclitaxel resulted in a significant improvement in progression-free survival (PFS) compared with placebo plus carboplatin and paclitaxel, in patients with germline BRCA1 or BRCA2 (BRCA1/2)-mutated, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We now report final overall survival (OS) data. (Source: European Journal of Cancer)
Source: European Journal of Cancer - January 27, 2024 Category: Cancer & Oncology Authors: V éronique Diéras, Hyo S. Han, Hans Wildiers, Michael Friedlander, Jean-Pierre Ayoub, Shannon L. Puhalla, Delphine Loirat, Christine Ratajczak, Hephzibah Adamu, Vincent Girardi, Banu K. Arun Tags: Original Research Source Type: research
